Goldman Sachs Group is a leading global investment banking, securities, and investment management firm that provides a wide range of financial services to a diverse client base, including corporations, financial institutions, governments, and individuals. The company engages in various activities, including financial advisory services, underwriting of capital market transactions, asset management, and market making in securities and commodities. It is known for its expertise in mergers and acquisitions, risk management, and investment strategy, leveraging its extensive research capabilities and global reach to deliver innovative solutions in an ever-evolving financial landscape. Read More
Capricor Therapeutics (NASDAQ:CAPR) executives said the company is in active discussions with the U.S. Food and Drug Administration as it works toward a potential approval decision for deramiocel, its allogeneic cardiac-derived cell therapy for Duchenne muscular dystrophy.
Speaking at a Goldman Sac
BrightSpring Health Services (NASDAQ:BTSG) Chief Financial Officer Jennifer Phipps said the company’s recent growth has been driven by broad-based performance across its pharmacy and provider businesses, with specialty pharmacy remaining a key contributor.
Speaking at a Goldman Sachs healthcare ser
SpaceX will debut on the public markets, having raised at least $75 billion at a valuation of $1.78 trillion, making it the largest initial public offering ever.
Apogee Therapeutics (NASDAQ:APGE) executives outlined plans to advance zumilokibart, the company’s IL-13-targeting antibody, into late-stage development for atopic dermatitis while expanding the program into asthma and eosinophilic esophagitis, during a Goldman Sachs discussion hosted by lead biotec
Amylyx Pharmaceuticals (NASDAQ:AMLX) Co-Chief Executive Officer Justin Klee said the company is preparing for a key Phase 3 readout for avexitide, its lead program for post-bariatric hypoglycemia, during an appearance at the Goldman Sachs Global Healthcare Conference.
Klee described avexitide as a
What Happened? A number of stocks jumped in the afternoon session after the CPI data showed food away from home rose only 0.3% in May, well within manageable...
What Happened? A number of stocks jumped in the afternoon session after the CPI data showed food away from home rose only 0.3% in May, well within manageable...
What Happened? A number of stocks jumped in the afternoon session after markets rotated into defensive names following the release of the May CPI report. The...
What Happened? A number of stocks jumped in the afternoon session after markets rotated into defensive names following the release of the May CPI report. The...
What Happened? A number of stocks jumped in the afternoon session after markets rotated into defensive names following the release of the May CPI report. The...
What Happened? A number of stocks jumped in the afternoon session as markets rotated into defensive names following the release of the May CPI report. The he...
What Happened? Shares of financial services company Robinhood (NASDAQ:HOOD) jumped 6.4% in the afternoon session after it received regulatory approval for it...
Alkermes (NASDAQ:ALKS) executives said the company is entering a period of heightened execution as it advances its orexin agonist program into late-stage development, integrates Avadel and prepares for a planned leadership transition.
Speaking at the Goldman Sachs Global Healthcare Conference, Chai
Altimmune (NASDAQ:ALT) management used an appearance at the Goldman Sachs Global Healthcare Conference to outline the company’s focus on pemvidutide, its lead metabolic and liver disease drug candidate, and to discuss the planned Phase 3 program in metabolic dysfunction-associated steatohepatitis, o
The SpaceX IPO has Wall Street debating trillion-dollar valuations. Luke Lango argues the selloff it triggered is actually the buying opportunity investors have been waiting for in Corning, Ciena, Broadcom, and Redwire.
CG Oncology (NASDAQ:CGON) Chief Executive Officer Arthur outlined the company’s upcoming clinical and regulatory milestones for cretostimogene during a presentation at the Goldman Sachs Global Healthcare Conference, emphasizing data readouts, a potential filing and commercial preparation in non-musc
